Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study

References

• IDF Clinical Guidelines Task Force. Global Guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005
   Google Scholar
• Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2–3 study). Diabetes Obes Metab 2006;8:58–66
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006;114:511–19
   PubMed Web of Science ®Google Scholar
• Liebl A, Prager R, Kaiser M, et al. The PREFER study: both biphasic insulin aspart 30 twice-daily and basal-bolus using insulin detemir and insulin aspart enabled patients with type 2 diabetes to achieve HbA1c target < 7.0%. Diabetologia 2006; 49 (Suppl 1):610–11
   Google Scholar
• Bolli GB, Di Marchi RD, Park GB, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151–67
   PubMed Web of Science ®Google Scholar
• Brange J, Volund A. Insulin analogs with improved pharmaco-kinetic profiles. Adv Drug Deliv Rev 1999;35:307–35
   PubMed Web of Science ®Google Scholar
• Heinemann L. Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995;12:449–50
   PubMed Web of Science ®Google Scholar
• Overmann H, Heinemann L. Injection-meal interval: recommend ations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137–42
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmaco-dynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56:399–403
   Google Scholar
• McSorley, Bell PM, Jacobsen LV, et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002;24:530–9
   PubMed Web of Science ®Google Scholar
• McNally PG, Dean JD, Morris AD, et al. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007;30:1044–8
   PubMed Web of Science ®Google Scholar
• Rizvi AA, Ligthelm RJ. The use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007;2:68–79
   Google Scholar
• Boehm BO, Home PD, Kamp BNM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19: 393–9
   Google Scholar
• Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Inter Med 2004;15:496–502
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15–35
   PubMedGoogle Scholar
• Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin regimens (Results from the Austrian Biaspart study). Horm Metab Res 2005;37:684–9
   PubMed Web of Science ®Google Scholar
• Schwartz S, Sievers R, Strange P, et al., for the INS-2061 study team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis. Diabetes Care 2003;26: 2238–43
   Google Scholar
• Raskin PR, Hollander PA, Lewin A, et al., on behalf of the INITIATE study group. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007;18: 56–62
   Google Scholar
• Raskin P, Allen E, Hollander P, et al., for the INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analog. Diabetes Care 2005;28: 260–5
   Google Scholar
• Davidson J, Vexiau P, Cucinotta D, et al. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005;27(Suppl B):S75–88
   Google Scholar
• Raz I, Mouritzen U, Vaz J, et al. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. Clin Ther 2003;25:3109–23
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ, Borzi V, Gumprecht J, et al. Importance of observational studies in clinical practice. Clin Ther 2007;29:1284–92
   Web of Science ®Google Scholar